SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
151
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PolarityTE, Inc. of Class Action Lawsuit and Upcoming Deadline – COOL

NEW YORK, Aug. 04, 2018 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PolarityTE (“PolarityTE” or the “Company”) (NASDAQ:  COOL) and certain of its officers.   The class action, filed in United States District Court, District of Utah, and docketed under 18-cv-00541, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired PolarityTE securities between March 31, 2017 and June 22, 2018, both dates inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased PolarityTE securities between March 31, 2017, and June 22, 2018, both dates inclusive, you have until August 27, 2018, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com .   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here to join this class action]

PolarityTE purports to be a commercial-stage biotechnology and regenerative biomaterials company focused on discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences.  The Company’s key development is SkinTE, which is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument.  Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. 

On April 7, 2017, PolarityTE announced the closing of a transaction through which the Company purchased Dr. Denver Lough’s (“Lough”) pending Patent #14/954,335 (the “Patent”) in exchange for over $104 million of PolarityTE stock.

Just one week prior to the closing of the transaction, on March 31, 2017, Dr. Lough received a notice of non-final rejection of the Patent by the U.S. Patent and Trademark Office (“USPTO”).  The USPTO mailed Dr. Lough a letter indicating the non-final rejection of the Patent on April 7, 2017—the same day that the transaction closed.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Specifically, PolarityTE made false and/or misleading statements and/or failed to disclose that: (i) the USPTO issued a notice of non-final rejection of the Patent before PolarityTE acquired it in exchange for over $104 million of Company stock in April 2017; (ii) the USPTO issued a final rejection of the Patent on June 4, 2018; and (iii) as a result, PolarityTE’s public statements were materially false and misleading at all relevant times.

On June 25, 2018, Citron Research published a report exposing the Defendants’ failure to disclose the USPTO’s March 31, 2017 notice of non-final rejection of the Patent and highlighting the USPTO’s June 4, 2018, final rejection of the Patent. 

On this news, PolarityTE’s share price fell $10.59, or 27.3%, to close at $28.14 on June 26, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com 888-476-6529 ext. 9980

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hot Dog Marketing Makes a Serious Public-Sector Push

Updated Category News Views 89

Five well-connected Central Texas names can tell you plenty about where an agency intends to hunt next. Hot Dog Marketing's Nov. 18 move is not some shiny rebrand with confetti tossed at the wall. The Austin-based firm is putting strategic communications beside its established marketing work and bringing in a five-member Strategic Advisory Council aimed squarely at...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 52

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Nvidia Lawsuit Allegations Put Disclosure Risk in Focus

Updated Category News Views 30

A lawsuit notice can turn a roaring chip story sour in a hurry, and this one deserves a cold, careful read rather than the usual internet stampede. DJS Law Group says it has filed a securities class action against NVIDIA, alleging that the company made materially false and misleading statements during a stated class period running from October 9, 2025 through November 8,...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 110

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 102

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Biohaven's BHV-1530 Data Earns a Careful Investor Look

Updated Category News Views 49

Thirty heavily treated cancer patients can make a molecule look brilliant or merely lucky, and BHV-1530 is still living in that uncomfortable early-stage gap. Biohaven presented Phase 1 results at ENA 2026 that deserve real attention, particularly because the responses showed up in patients with few attractive remaining options. But this is not the moment to confuse a...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading
Limina’s Amberflo Deal Makes AI Usage Visible at Scale

Updated Category News Views 26

Enterprise AI has created a billing fog, and Limina just bought itself a flashlight. Its merger with Amberflo, completed on October 30 and announced November 19, brings metering, cost attribution, and billing technology fully inside Limina’s data-governance platform. No price was disclosed, which is irritating but ordinary for a transaction involving companies that do...

Continue Reading
Brightstar Picks Warsop for Its Next CEO Chapter Ahead

Updated Category News Views 112

A Handoff With Plenty Riding on the Rails A lottery supplier changing captains is not usually fireworks, but this one deserves a hard look. Brightstar Lottery has named Thomas Warsop to replace Vince Sadusky as chief executive officer and board member effective January 1, 2027. Sadusky is retiring from both posts on that date. The company is telegraphing an orderly baton...

Continue Reading

Top 5 Most Recently Viewed Articles

Coveo Earns Recognition as Leader in Generative AI Solutions

Updated Category News Views 244

Coveo Achieves AWS Generative AI Competency Coveo, a frontrunner in the field of AI-Relevance, is thrilled to announce its esteemed recognition for achieving the Amazon Web Services (AWS) Generative AI Competency. This designation not only highlights Coveo's exceptional capabilities but also emphasizes its role in helping businesses harness the power of AI to optimize...

Continue Reading
Legal Inquiry Regarding MediaAlpha, Inc. (MAX) Securities Issues

Updated Category News Views 151

Understanding the Securities Investigation of MediaAlpha, Inc. Investors are currently facing a troubling time as MediaAlpha, Inc. (MAX) finds itself under scrutiny. This investigation, brought forth by a prominent law firm, focuses on potential violations of federal securities laws. The significant implication of these allegations has led many investors to seek clarity...

Continue Reading
Rapid Growth in Data Center Liquid Cooling Market Forecasted

Updated Category News Views 159

Overview of the Data Center Liquid Cooling Market The Data Center Liquid Cooling Market has become a crucial focus in modern technology, with its market size projected to rise from USD 2.99 billion to USD 17.28 billion. This significant growth, a Compound Annual Growth Rate (CAGR) of 21.54% from 2024 to 2032, indicates a transitioning landscape in data management...

Continue Reading
Eupraxia Pharmaceuticals Shares Exciting Updates on EoE Trial

Updated Category News Views 327

Eupraxia Pharmaceuticals' Latest Trial Results for EP-104GI Eupraxia Pharmaceuticals Inc. (TSX: EPRX) has reported exciting news regarding its ongoing clinical trial for the treatment of eosinophilic esophagitis (EoE) with EP-104GI. This treatment aims to alleviate symptoms and improve the quality of life for patients suffering from this challenging condition. Highlights...

Continue Reading
Innovative Robotics Solutions Set to Transform Warehousing

Updated Category News Views 253

Revolutionizing Warehouse Operations with Robotics Autonomous forklifts are taking a leap forward by adapting into existing warehouse environments, promising a quick return on investment. The robotics innovator, Riibotics, is poised to present its innovative solutions at RoboBusiness 2025. This event is taking place at the Santa Clara Convention Center, where Riibotics...

Continue Reading